N/A
N=13
Gaming Technology to Engage Adolescent Sickle Cell Patients in Pain Management
Sickle Cell Disease
Bottom Line
View on ClinicalTrials.gov: NCT03291613 ↗Enrolled (actual)
13
Serious AEs
0.0%
Results posted
Feb 2019
Primary outcome: Primary: System Usability Questionnaire — 86.67 units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Pinpoint App (Other)
- Age
- Pediatric, Adult, Older Adult · 13+ yrs
- Sex
- All
- Sponsor
- Klein Buendel, Inc.
- Primary completion
- Sep 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY System Usability Questionnaire |
86.67 | — |
Summary
Sickle cell disease (SCD) is a common genetic disorder characterized by episodes of pain, yet assessments to identify type, intensity, frequency, and phase of pain among SCD adolescents is lacking. Research shows that interactive gaming technology can enhance adolescents' learning, and can be especially effective in delivering health-related messages and tools to improve their self-care. Pinpoint is an interactive gaming tablet app that will be developed with the significant input of clinical experts to assist SCD teens with better identification and self-report of their pain.
Eligibility Criteria
Phone Interview, Focus Group, and Usability Inclusion Criteria:
- Be 13-17 years of age
- Be diagnosed with Sickle Cell Disease
- Able to read and speak English
- Able to assent to participate
Phone Interview, Focus Group, and Usability Exclusion Criteria:
- Not 13-17 years of age
- Not diagnosed with Sickle Cell Disease
- Unable to read and speak English
- Unable to assent to participate
Healthcare Provider Interview Inclusion Criteria:
- Be a healthcare provider to teens with sickle cell disease
- Be 18 years of age or older
- Able to read and speak English
- Able to consent to participate
Healthcare Provider Interview Exclusion Criteria:
- Not a healthcare provider to teens with sickle cell disease
- Not 18 years of age or older
- Unable to read and speak English
- Unable to consent to participate
Data sourced from ClinicalTrials.gov (NCT03291613). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.